Treatment Modalities for Lymphocytic and Neutrophilic Scarring Alopecia

    Ogechi Ezemma, Shivali Devjani, Kristen J. Kelley, Maryanne M. Senna
    Image of study
    TLDR Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
    The document discusses the treatment of primary cicatricial alopecia (PCA), a group of disorders causing permanent hair loss. Early intervention is crucial and aims to reduce symptoms, slow disease progression, and improve hair density. Treatments for mild lymphocytic PCA include topical and intralesional medications, hydroxychloroquine, and phototherapy. Severe cases may require mycophenolate mofetil, methotrexate, cyclosporine, pioglitazone, dutasteride, and Janus kinase inhibitors. For neutrophilic PCA, treatments aim to reduce inflammation and bacterial load, with first-line treatments including benzoyl peroxide wash, topical steroids, steroid scalp injections, and oral antibiotics. Other treatments mentioned include oral prednisone, isotretinoin, systemic immunomodulators like dapsone, adalimumab, infliximab, and topical metformin for hair regrowth. The document does not provide the number of patients involved in the studies of these treatments.
    Discuss this study in the Community →

    Research cited in this study

    10 / 10 results

    Related Community Posts Join

    6 / 282 results
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 3 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community We need to keep these snake oil companies accountable.

      in Treatment  121 upvotes 5 months ago
      Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

    Related Research

    4 / 4 results